Selumetinib Shrinks NF1-Plexiform Neurofibromas in Adults, Too

(MedPage Today) — CHICAGO — Selumetinib (Koselugo) significantly improved response rates in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas, the phase III KOMET trial showed.
After 16 cycles…